Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thrombin Pathway in 'Trial of PeriOperative Endocrine Therapy Individualising Care' [SUBSTUDY OF 700029612]

X
Trial Profile

Thrombin Pathway in 'Trial of PeriOperative Endocrine Therapy Individualising Care' [SUBSTUDY OF 700029612]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anastrozole (Primary) ; Letrozole (Primary) ; Antineoplastics
  • Indications Early breast cancer
  • Focus Pharmacodynamics
  • Acronyms T-POETIC-v1
  • Most Recent Events

    • 13 Dec 2013 Accrual to date is 87% according to United Kingdom Clinical Research Network.
    • 14 Nov 2013 Planned end date changed from 31 Oct 2013 to 31 Dec 2013 as reported by United Kingdom Clinical Research Network record.
    • 13 Nov 2013 Accrual to date is 82% according to United Kingdom Clinical Research Network.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top